Ferguson Wellman Capital Management Inc. Buys Shares of 2,600 Ascendis Pharma A/S $ASND

Ferguson Wellman Capital Management Inc. purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,600 shares of the biotechnology company’s stock, valued at approximately $693,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Advisory Services Network LLC acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at $26,000. Arax Advisory Partners lifted its stake in Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 104 shares in the last quarter. Leonteq Securities AG acquired a new position in Ascendis Pharma A/S during the 4th quarter worth about $36,000. Caitong International Asset Management Co. Ltd acquired a new position in Ascendis Pharma A/S during the 4th quarter worth about $42,000. Finally, Global Retirement Partners LLC boosted its holdings in Ascendis Pharma A/S by 111.9% during the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 113 shares during the period.

More Ascendis Pharma A/S News

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: HC Wainwright initiated coverage of Ascendis Pharma with a Buy rating and a $345 price target, implying approximately 39% potential upside from the referenced share price. The bullish stance provides positive analyst support for ASND. HC Wainwright initiates coverage
• Positive Sentiment: HC Wainwright analyst M. Kapoor projected Ascendis Pharma will earn $3.93 per share in fiscal 2026, broadly above the cited consensus estimate of $3.90, and expects quarterly EPS of $1.16 in Q3 2026 and $1.66 in Q4 2026. HC Wainwright FY2026 estimates
• Positive Sentiment: The firm forecast substantial earnings growth in 2027, with quarterly EPS estimates rising from $1.76 in Q1 to $4.42 in Q4, resulting in projected full-year EPS of $11.88. If achieved, that would represent a significant improvement over the 2026 forecast and supports the analyst’s optimistic valuation. HC Wainwright FY2027 estimates

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $247.91 on Friday. The firm has a market capitalization of $15.46 billion, a price-to-earnings ratio of 19.23 and a beta of 0.39. The firm’s fifty day simple moving average is $255.74 and its 200-day simple moving average is $239.08. Ascendis Pharma A/S has a twelve month low of $186.05 and a twelve month high of $282.15. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. Equities analysts forecast that Ascendis Pharma A/S will post 3.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on ASND. HC Wainwright began coverage on Ascendis Pharma A/S in a research report on Thursday. They issued a “buy” rating and a $345.00 target price for the company. Oppenheimer reissued an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, June 9th. Evercore reissued an “outperform” rating and issued a $329.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. BMO Capital Markets assumed coverage on shares of Ascendis Pharma A/S in a report on Tuesday, August 18th. They issued an “outperform” rating and a $319.00 price objective for the company. Finally, Barclays cut their target price on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S has an average rating of “Buy” and a consensus price target of $302.68.

Insider Transactions at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime acquired 2,000 shares of the stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, with a total value of $492,660.00. Following the transaction, the director owned 2,900 shares in the company, valued at $714,357. The trade was a 222.22% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 40.00% of the stock is owned by company insiders.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.